-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic syndrome with limited treatment optio.
Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic syndrome with limited treatment optio.
On July 15, 2022, Sun Ying, Guo Dong and Jia Zhanjun of Xuzhou Medical University jointly published a research paper titled " InhibitionofmPGES-2amelioratesnon-alcoholicsteatohepatitisbyactivatingNR1D1viaheme "in Hepatology (IF=17) , the study found that compared with control mice , mPGES-2-deficient mice had reduced liver lipid accumulation and improved liver injury, inflammation, and fibrosi.
In conclusion, this study demonstrates the pathogenic role of mPGES-2 and outlines the mechanism mediating NAFLD, thereby highlighting the therapeutic potential of mPGES-2 inhibition in hepatic steatosis and steatohepatit.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting approximately 25% of the general populati.
Despite recent advances in hepatology, the pathogenesis of NASH remains uncle.
Microsomal prostaglandin E synthase 1 (mPGES-1), mPGES-2, and cytoplasmic prostaglandin E2 synthase (cPGES) are the three known prostaglandin E2 (PGE2) synthas.
mPGES-2 catalyzes the conversion of prostaglandin H2 (PGH2) to malondialdehyde (MDA) or PGE2, with or without heme bindi.
Article pattern diagram (picture from Hepatology)
Article pattern diagram (picture from Hepatology)mPGES-2 forms a complex with GSH and heme and is a natural ligand for nuclear receptor subfamily 1 group D member 1 (NR1D1, also known as REV-ERB.
mPGES-2 forms a complex with GSH and heme and is a natural ligand for nuclear receptor subfamily 1 group D member 1 (NR1D1, also known as REV-ERB.
In the present study, we explored how mPGES-2 affects NAFLD progression and whether NR1D1 is involved in mediating the effects of mPGES-2 inducti.
The study used different mouse types [ mPGES-2 systemic knockout mice and hepatocyte-specific mPGES-2 deficient mice fed a high-fat diet (HFD) or methionine-choline deficient (MCD) diet and diabetic db/db mPGES-2 knockout mice] to evaluate the effect of mPGES-2 on NAFLD progressi.
Mice were treated with the mPGES-2 inhibitor SZ0232 to further determine the effect of mPGES-2 on NAF.
The findings suggest that mPGES-2 may be a new therapeutic target for hepatic steatosis and NA.
We explored how mPGES-2 affects NAFLD progression and whether NR1D1 is involved in mediating the effects of mPGES-2 inducti.
mPGES-2 may be a new therapeutic target for hepatic steatosis and NA.
mPGES-2 may be a new therapeutic target for hepatic steatosis and NA.
leave a message here
